Targeting cancer-initiating cell drug-resistance: A Sroadmap to a new-generation of cancer therapies?

Angela Alama, Anna Maria Orengo, Silvano Ferrini, Rosaria Gangemi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating cells display a range of self-defense systems that include almost all mechanisms of drug-resistance. Different molecular pathways and markers, identified in this malignant sub-population, are becoming targets for novel compounds and for monoclonal antibodies, which may be combined with conventional drugs. These interventions might eliminate drug-resistant cancer-initiating cells and lead to remission or cure of cancer patients.

Original languageEnglish
Pages (from-to)435-442
Number of pages8
JournalDrug Discovery Today
Volume17
Issue number9-10
DOIs
Publication statusPublished - May 2012

Fingerprint

Drug Resistance
Neoplasms
Therapeutics
Health Services Needs and Demand
Treatment Failure
Pharmaceutical Preparations
Carcinogenesis
Monoclonal Antibodies
Recurrence

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Targeting cancer-initiating cell drug-resistance : A Sroadmap to a new-generation of cancer therapies? / Alama, Angela; Orengo, Anna Maria; Ferrini, Silvano; Gangemi, Rosaria.

In: Drug Discovery Today, Vol. 17, No. 9-10, 05.2012, p. 435-442.

Research output: Contribution to journalArticle

@article{c2d2ca93039743f580ea6f080f76e9e8,
title = "Targeting cancer-initiating cell drug-resistance: A Sroadmap to a new-generation of cancer therapies?",
abstract = "The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating cells display a range of self-defense systems that include almost all mechanisms of drug-resistance. Different molecular pathways and markers, identified in this malignant sub-population, are becoming targets for novel compounds and for monoclonal antibodies, which may be combined with conventional drugs. These interventions might eliminate drug-resistant cancer-initiating cells and lead to remission or cure of cancer patients.",
author = "Angela Alama and Orengo, {Anna Maria} and Silvano Ferrini and Rosaria Gangemi",
year = "2012",
month = "5",
doi = "10.1016/j.drudis.2011.02.005",
language = "English",
volume = "17",
pages = "435--442",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "9-10",

}

TY - JOUR

T1 - Targeting cancer-initiating cell drug-resistance

T2 - A Sroadmap to a new-generation of cancer therapies?

AU - Alama, Angela

AU - Orengo, Anna Maria

AU - Ferrini, Silvano

AU - Gangemi, Rosaria

PY - 2012/5

Y1 - 2012/5

N2 - The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating cells display a range of self-defense systems that include almost all mechanisms of drug-resistance. Different molecular pathways and markers, identified in this malignant sub-population, are becoming targets for novel compounds and for monoclonal antibodies, which may be combined with conventional drugs. These interventions might eliminate drug-resistant cancer-initiating cells and lead to remission or cure of cancer patients.

AB - The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating cells display a range of self-defense systems that include almost all mechanisms of drug-resistance. Different molecular pathways and markers, identified in this malignant sub-population, are becoming targets for novel compounds and for monoclonal antibodies, which may be combined with conventional drugs. These interventions might eliminate drug-resistant cancer-initiating cells and lead to remission or cure of cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84857144607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857144607&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2011.02.005

DO - 10.1016/j.drudis.2011.02.005

M3 - Article

C2 - 21315830

AN - SCOPUS:84857144607

VL - 17

SP - 435

EP - 442

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 9-10

ER -